About 30% of patients with papillary thyroid cancer (PTC) experience persistent/recurrent disease within 10 years after an initial treatment, serum thyroglobulin (Tg) representing the gold standard for surveillance. This evidence concerns the gene TG and thyroid gland papillary carcinoma.